In 2003, there seemed to be good reasons to leave weight-loss drugs out of the benefit, write Inmaculada Hernandez of the University of California, San Diego, and coauthors in their September 2023 editorial in the Journal of General Internal Medicine, Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform. When members of Congress worked on the Part D benefit, the drugs available on the market were known to have limited effectiveness and unpleasant side effects
Ozempic has years more real-world data and is specifically approved to reduce the risk of major cardiovascular events heart attack, stroke and to slow the progression of diabetic kidney disease in people with type 2 diabetes
The VA said it will enroll more than 600 veterans in the study, which will evaluate semaglutide, a GLP-1 receptor agonist widely used to treat Type 2 diabetes and obesity
Why Did North America Dominate the GLP-1 Analogues Market in 2025
Ive been seeing some of our local brands claiming to be pregnancy safe product containing Beta Arbutin
It's fantastic for smaller, more precise doses (micro-dosing), as it allows you to measure tiny amounts more accurately